Annual CFO
-$70.23 M
-$10.63 M-17.84%
December 31, 2023
Summary
- As of February 6, 2025, OCUL annual cash flow from operations is -$70.23 million, with the most recent change of -$10.63 million (-17.84%) on December 31, 2023.
- During the last 3 years, OCUL annual CFO has fallen by -$16.68 million (-31.15%).
- OCUL annual CFO is now -458.08% below its all-time high of -$12.59 million, reached on December 31, 2012.
Performance
OCUL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$36.56 M
-$11.76 M-47.40%
September 30, 2024
Summary
- As of February 6, 2025, OCUL quarterly cash flow from operations is -$36.56 million, with the most recent change of -$11.76 million (-47.40%) on September 30, 2024.
- Over the past year, OCUL quarterly CFO has dropped by -$28.83 million (-372.83%).
- OCUL quarterly CFO is now -1182.77% below its all-time high of -$2.85 million, reached on September 30, 2013.
Performance
OCUL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$117.70 M
-$28.83 M-32.44%
September 30, 2024
Summary
- As of February 6, 2025, OCUL TTM cash flow from operations is -$117.70 million, with the most recent change of -$28.83 million (-32.44%) on September 30, 2024.
- Over the past year, OCUL TTM CFO has dropped by -$52.96 million (-81.81%).
- OCUL TTM CFO is now -3385.40% below its all-time high of -$3.38 million, reached on March 31, 2013.
Performance
OCUL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
OCUL Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.8% | -372.8% | -81.8% |
| 3 y3 years | -31.1% | -181.6% | -107.8% |
| 5 y5 years | -42.7% | -87.1% | -51.7% |
OCUL Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -17.8% | at low | -372.8% | at low | -104.3% | at low |
| 5 y | 5-year | -31.1% | +9.5% | -485.3% | at low | -126.1% | at low |
| alltime | all time | -458.1% | +9.5% | -1182.8% | at low | -3385.4% | at low |
Ocular Therapeutix Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$36.56 M(+47.4%) | -$117.70 M(+32.4%) |
| Jun 2024 | - | -$24.80 M(-26.8%) | -$88.88 M(+5.6%) |
| Mar 2024 | - | -$33.89 M(+50.9%) | -$84.15 M(+19.8%) |
| Dec 2023 | -$70.23 M(+17.8%) | -$22.45 M(+190.4%) | -$70.23 M(+8.5%) |
| Sep 2023 | - | -$7.73 M(-61.5%) | -$64.74 M(-7.7%) |
| Jun 2023 | - | -$20.07 M(+0.5%) | -$70.17 M(+15.1%) |
| Mar 2023 | - | -$19.97 M(+17.8%) | -$60.98 M(+2.3%) |
| Dec 2022 | -$59.60 M(-9.1%) | -$16.96 M(+28.8%) | -$59.60 M(+3.1%) |
| Sep 2022 | - | -$13.17 M(+21.1%) | -$57.80 M(+0.3%) |
| Jun 2022 | - | -$10.88 M(-41.5%) | -$57.61 M(-13.7%) |
| Mar 2022 | - | -$18.60 M(+22.7%) | -$66.79 M(+1.9%) |
| Dec 2021 | -$65.55 M(+22.4%) | -$15.15 M(+16.7%) | -$65.55 M(+15.7%) |
| Sep 2021 | - | -$12.98 M(-35.3%) | -$56.64 M(-1.2%) |
| Jun 2021 | - | -$20.06 M(+15.5%) | -$57.32 M(+10.1%) |
| Mar 2021 | - | -$17.36 M(+177.9%) | -$52.06 M(-2.8%) |
| Dec 2020 | -$53.55 M(-31.0%) | -$6.25 M(-54.3%) | -$53.55 M(-19.8%) |
| Sep 2020 | - | -$13.66 M(-7.7%) | -$66.78 M(-8.1%) |
| Jun 2020 | - | -$14.80 M(-21.5%) | -$72.66 M(-5.7%) |
| Mar 2020 | - | -$18.85 M(-3.1%) | -$77.05 M(-0.7%) |
| Dec 2019 | -$77.58 M(+57.6%) | -$19.47 M(-0.4%) | -$77.58 M(+8.1%) |
| Sep 2019 | - | -$19.54 M(+1.9%) | -$71.76 M(+13.7%) |
| Jun 2019 | - | -$19.18 M(-1.1%) | -$63.09 M(+12.4%) |
| Mar 2019 | - | -$19.39 M(+42.0%) | -$56.14 M(+14.0%) |
| Dec 2018 | -$49.23 M | -$13.65 M(+25.5%) | -$49.23 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$10.87 M(-11.1%) | -$45.96 M(-7.1%) |
| Jun 2018 | - | -$12.23 M(-1.9%) | -$49.47 M(+2.3%) |
| Mar 2018 | - | -$12.47 M(+20.1%) | -$48.37 M(-4.2%) |
| Dec 2017 | -$50.47 M(+48.4%) | -$10.38 M(-27.8%) | -$50.47 M(+5.8%) |
| Sep 2017 | - | -$14.38 M(+29.2%) | -$47.70 M(+17.3%) |
| Jun 2017 | - | -$11.13 M(-23.6%) | -$40.65 M(+3.4%) |
| Mar 2017 | - | -$14.58 M(+91.5%) | -$39.32 M(+15.6%) |
| Dec 2016 | -$34.00 M(+0.8%) | -$7.61 M(+3.8%) | -$34.00 M(-2.9%) |
| Sep 2016 | - | -$7.33 M(-25.2%) | -$35.02 M(-6.3%) |
| Jun 2016 | - | -$9.80 M(+5.9%) | -$37.39 M(+3.5%) |
| Mar 2016 | - | -$9.26 M(+7.2%) | -$36.12 M(+7.0%) |
| Dec 2015 | -$33.74 M(+64.6%) | -$8.64 M(-11.0%) | -$33.74 M(+9.8%) |
| Sep 2015 | - | -$9.70 M(+13.7%) | -$30.73 M(+12.3%) |
| Jun 2015 | - | -$8.53 M(+24.0%) | -$27.37 M(+17.2%) |
| Mar 2015 | - | -$6.88 M(+22.3%) | -$23.35 M(+13.9%) |
| Dec 2014 | -$20.50 M(+62.1%) | -$5.63 M(-11.2%) | -$20.50 M(+11.8%) |
| Sep 2014 | - | -$6.33 M(+40.4%) | -$18.33 M(+23.5%) |
| Jun 2014 | - | -$4.51 M(+12.1%) | -$14.84 M(+11.7%) |
| Mar 2014 | - | -$4.03 M(+16.4%) | -$13.29 M(+5.1%) |
| Dec 2013 | -$12.64 M(+0.5%) | -$3.46 M(+21.3%) | -$12.64 M(+37.6%) |
| Sep 2013 | - | -$2.85 M(-3.7%) | -$9.19 M(+45.0%) |
| Jun 2013 | - | -$2.96 M(-12.3%) | -$6.34 M(+87.7%) |
| Mar 2013 | - | -$3.38 M | -$3.38 M |
| Dec 2012 | -$12.59 M | - | - |
FAQ
- What is Ocular Therapeutix annual cash flow from operations?
- What is the all time high annual CFO for Ocular Therapeutix?
- What is Ocular Therapeutix annual CFO year-on-year change?
- What is Ocular Therapeutix quarterly cash flow from operations?
- What is the all time high quarterly CFO for Ocular Therapeutix?
- What is Ocular Therapeutix quarterly CFO year-on-year change?
- What is Ocular Therapeutix TTM cash flow from operations?
- What is the all time high TTM CFO for Ocular Therapeutix?
- What is Ocular Therapeutix TTM CFO year-on-year change?
What is Ocular Therapeutix annual cash flow from operations?
The current annual CFO of OCUL is -$70.23 M
What is the all time high annual CFO for Ocular Therapeutix?
Ocular Therapeutix all-time high annual cash flow from operations is -$12.59 M
What is Ocular Therapeutix annual CFO year-on-year change?
Over the past year, OCUL annual cash flow from operations has changed by -$10.63 M (-17.84%)
What is Ocular Therapeutix quarterly cash flow from operations?
The current quarterly CFO of OCUL is -$36.56 M
What is the all time high quarterly CFO for Ocular Therapeutix?
Ocular Therapeutix all-time high quarterly cash flow from operations is -$2.85 M
What is Ocular Therapeutix quarterly CFO year-on-year change?
Over the past year, OCUL quarterly cash flow from operations has changed by -$28.83 M (-372.83%)
What is Ocular Therapeutix TTM cash flow from operations?
The current TTM CFO of OCUL is -$117.70 M
What is the all time high TTM CFO for Ocular Therapeutix?
Ocular Therapeutix all-time high TTM cash flow from operations is -$3.38 M
What is Ocular Therapeutix TTM CFO year-on-year change?
Over the past year, OCUL TTM cash flow from operations has changed by -$52.96 M (-81.81%)